Quarterly Report · 10-Q

Zymeworks Inc.

ZYMENASDAQEQUITYCurrent

Quarterly Report

Filed May 7, 2026Accepted May 7, 2026, 4:15 PM EDTCIK 1937653Accession 0001937653-26-000034

Company context

Zymeworks is a global biotechnology company building a diversified portfolio of healthcare assets designed to generate durable cash flows while advancing innovative medicines for difficult-to-treat diseases. Zymeworks’ asset and royalty aggregation strategy combines a growing portfolio of commercial and near-commercial assets, including YUPELRI® (revefenacin), with a differentiated internal research and development engine. Zymeworks’ portfolio also includes Ziihera® (zanidatamab-hrii), a HER2-targeted bispecific antibody discovered and developed by Zymeworks and commercialized through global partnerships with Jazz Pharmaceuticals and BeOne Medicines, and pasritamig, a clinical-stage multispecific antibody developed by Johnson & Johnson using Zymeworks’ proprietary antibody engineering technologies.

Current securities

ZYMENASDAQ · EQUITY · Current

Recent company filings

Registered securities in this filing

ZYMEWORKS INC. · 10-Q · Filed 2026-05-07

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, $0.00001 par value per share

Symbol: ZYME
Exchange: NASDAQ
Classification: COMMON
Status: Current

Filing context

Context: c-1

Dimensions: Not supplied

Accession 000193765326000034 · 1 registered-security cover member

Read the exact SEC filing ↗

As-filed source

Primary evidence

As filedOpen full document ↗

Get the free weekly BCS email.